TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16595206

Group type: EXPERIMENTAL
Intervention: DMPA-SC (104 mg)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Leuprolide acetate (11.25 mg)
Number of subjects: 274
Study: 12874697

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenous infusion)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11874941

Group type: EXPERIMENTAL
Intervention: alpha-Tocopherol supplementation (1,200 IU/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 72
Study: 9428817

Group type: EXPERIMENTAL
Intervention: Daclizumab (1.0 mg/kg body weight, administered intravenously before transplantation and once every other week afterward for a total of five doses)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo (administered intravenously before transplantation and once every other week afterward for a total of five doses)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 8608061

Group type: EXPERIMENTAL
Intervention: Prophylactic CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: No CSF
Number of subjects: 0
Study: 2501243

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus mitomycin C
Number of subjects: 120

Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 120
Study: 831472

Group type: EXPERIMENTAL
Intervention: Addition of hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Addition of heparin 1,000 units to each liter of intravenous fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Addition of heparin 500 units and hydrocortisone phosphate 1 mg to each liter of intravenous fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Addition of heparin 1,000 units and hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Filtration of intravenous solutions through a 0.22‐mum inline filter
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 120
Study: 31938571

Group type: EXPERIMENTAL
Intervention: Electrical Interferential Current stimulation (IFC) with medium frequency of 4000 HZ
Number of subjects: 46

Group type: COMPARATOR
Intervention: Electrical Acupuncture (EAC) two times a week for a total of 10 sessions
Number of subjects: 46
Study: 31694152

Group type: EXPERIMENTAL
Intervention: Mixed flavonoid-caffeine (MFC) supplement (658 mg flavonoids, 214 mg caffeine)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mixed flavonoid-caffeine (MFC) supplement
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 28364726

Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 48
Study: 25936297

Group type: EXPERIMENTAL
Intervention: 0.1 g/kg l‐methionine to induce hyperhomocysteinemia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 500 ml whipping cream (30% fat) to induce hyperlipidemia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (baseline assessment)
Number of subjects: 25
Study: 23054169

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) coalitions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control coalitions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community Economic Problems scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTC coalitions
Number of subjects: 0
Study: 21270630

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen (2:1 mixture)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (sevoflurane in air-oxygen)
Number of subjects: 20
Study: 18800037

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil administered for up to 7 days
Number of subjects: 36
Study: 16490627

Group type: EXPERIMENTAL
Intervention: Ramipril, 2.5 mg 3 times/wk
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 46
Study: 15256981

Group type: EXPERIMENTAL
Intervention: Empirical treatment followed by Helicobacter pylori test and treat strategy (treat and test group)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Prompt upper gastrointestinal endoscopy (endoscopy group)
Number of subjects: 77
Study: 11078839

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the right eye
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the superior neuroretinal rim of the right eye
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the superior neuroretinal rim of the left eye
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the left eye
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the inferior temporal neuroretinal rim of the right eye
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser speckle flowgraphy measurement of square blur rate in the inferior temporal neuroretinal rim of the left eye
Number of subjects: 60
Study: 9305482

Group type: EXPERIMENTAL
Intervention: AIMg(OH)3 (280 mval/day)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg)
Number of subjects: 174

Group type: COMPARATOR
Intervention: AIMg(OH)3 and Ranitidine
Number of subjects: 174
Study: 8342399

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (4 micrograms/kg loading dose followed by 1 microgram/kg/h infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 20
Study: 30893689

Group type: EXPERIMENTAL
Intervention: Occlusive wrap applied immediately after birth
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard of care (no wrap)
Number of subjects: 28
Study: 29549193

Group type: EXPERIMENTAL
Intervention: ELEVIDA (self-guided online fatigue management programme)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 275
Study: 27639819

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 0.5 mg/kg, twice daily (max 60 mg/day) from day one until discharge
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D-dimer assay
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DUS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: D-dimer values
Number of subjects: 100
Study: 24708506

Group type: EXPERIMENTAL
Intervention: Participants from the United States sorting images of posed facial expressions with cues to emotion concepts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants from the Himba ethnic group sorting images of posed facial expressions without cues to emotion concepts.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants from both cultures sorting images of posed facial expressions with cues to emotion concepts.
Number of subjects: 0
Study: 22504187

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) simulator
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Box trainer
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 24
Study: 20214176

Group type: EXPERIMENTAL
Intervention: Topical hemostatic powder (THP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sterile compressed surgical sponge
Number of subjects: 24
Study: 18653654

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 102

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP
Number of subjects: 102
Study: 15640999

Group type: EXPERIMENTAL
Intervention: Decompressive cervical spine surgery
Number of subjects: 26
Study: 12496983

Group type: EXPERIMENTAL
Intervention: Periprostatic injection of 5 ml 1% lidocaine solution (2.5 ml bilaterally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 100
Study: 10502030

Group type: EXPERIMENTAL
Intervention: Pure pea starch
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cornstarch
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Crude pea flour
Number of subjects: 26
Study: 9156938

Group type: EXPERIMENTAL
Intervention: HIV-negative drug addicts (1986-87)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HIV-positive drug addicts
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: AIDS patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All investigated groups
Number of subjects: 91

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 91
Study: 1859008

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1 bolus followed by infusion of 160 microgram.kg‐1.min‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol (as in group B) and 66% N2O
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol (as in group B), 66% N2O (as in group C), and droperidol 75 micrograms.kg‐1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Halothane, 66% N2O, and droperidol 75 micrograms.kg‐1
Number of subjects: 120
Study: 6344981

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and high-dose methotrexate
Number of subjects: 65

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 65
Study: 31341170

Group type: EXPERIMENTAL
Intervention: SCN-resistant soybean cultivars infested with 2000 nematode eggs and 15 soybean aphids at V2 growth stage
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: SCN-susceptible soybean cultivars infested with 2000 nematode eggs and 15 soybean aphids at V2 growth stage
Number of subjects: 6
Study: 28617733

Group type: COMPARATOR
Intervention: Facility-based HIV testing and counseling (HTC)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 325
Study: 28925135

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii glycosides (20 mg, tid for 4 weeks, then 10 mg, tid) combined with gestrinone (2.5 mg on 1st and 4th day of menstrual cycle, then twice a week)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Gestrinone capsule (same intake method as treatment group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii glycosides combined with gestrinone
Number of subjects: 135
Study: 24366350

Group type: EXPERIMENTAL
Intervention: Free bednet distribution program
Number of subjects: 560
Study: 20664362

Group type: EXPERIMENTAL
Intervention: Visual Stimuli (VS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Auditory Stimuli (AS)
Number of subjects: 15
Study: 19418075

Group type: EXPERIMENTAL
Intervention: Psychosocial educational program (PSEP) consisting of an interactive seminar and the Back Book for reference material.
Number of subjects: 3792

Group type: COMPARATOR
Intervention: Control group (CG) with no education.
Number of subjects: 3792

Group type: EXPERIMENTAL
Intervention: Psychosocial educational program (PSEP)
Number of subjects: 3792
Study: 17578820

Group type: EXPERIMENTAL
Intervention: General practitioners
Number of subjects: 160

Group type: COMPARATOR
Intervention: Orthopaedic surgeons
Number of subjects: 160
Study: 15219610

Group type: EXPERIMENTAL
Intervention: Lorazepam (30 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11356439

Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 244
Study: 9492127

Group type: EXPERIMENTAL
Intervention: Injection within the wound (0.5 mL buffered lidocaine)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Injection through intact skin (0.5 mL buffered lidocaine)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: First injection (within wound) in group 1
Number of subjects: 63

Group type: COMPARATOR
Intervention: Second injection (intact skin) in group 1
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: First injection (intact skin) in group 2
Number of subjects: 63

Group type: COMPARATOR
Intervention: Second injection (within wound) in group 2
Number of subjects: 63
Study: 8113006

Group type: EXPERIMENTAL
Intervention: Topical timolol (0.25%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3381775

Group type: EXPERIMENTAL
Intervention: Half-strength formula (equal parts, 84 J/30 mL [20 cal/oz] formula and water)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Full-strength (FS) formula (84 J/30 mL [20 cal/oz])
Number of subjects: 50
Study: 30547963

Group type: EXPERIMENTAL
Intervention: Survivorship-focused healthcare visit
Number of subjects: 44

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 44
Study: 28151914

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study: 26559307

Group type: EXPERIMENTAL
Intervention: Modified trephine
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-speed drill
Number of subjects: 50
Study: 23596140

Group type: COMPARATOR
Intervention: Physician intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Physician plus patient intervention
Number of subjects: 1000
Study: 21775504

Group type: EXPERIMENTAL
Intervention: Uninterpretable Risk Score (URS) developed using clinical and patient variables (heart rate and coronary calcium).
Number of subjects: 9500

Group type: EXPERIMENTAL
Intervention: Increased heart rate and coronary artery calcium score.
Number of subjects: 9500

Group type: EXPERIMENTAL
Intervention: Uninterpretable results from CCTA.
Number of subjects: 9500
Study: 19840653

Group type: EXPERIMENTAL
Intervention: GT rotary files
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ProTaper rotary files
Number of subjects: 20

Group type: COMPARATOR
Intervention: ProTaper and GT rotary files
Number of subjects: 20
Study: 16624446

Group type: EXPERIMENTAL
Intervention: Cheeseburger stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: French fries (novel stimulus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cheeseburger (repeated stimulus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivated responding
Number of subjects: 0
Study: 15523983

Group type: EXPERIMENTAL
Intervention: Alcon CustomCornea LASIK
Number of subjects: 35

Group type: COMPARATOR
Intervention: VISX CustomVue LASIK
Number of subjects: 35

Group type: COMPARATOR
Intervention: CustomVue LASIK
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 35
Study: 11878727

Group type: EXPERIMENTAL
Intervention: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural bupivacaine (Bupi)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GA, paracetamol, NSAID, intraoperative epidural lidocaine and 24‐h postoperative epidural saline (Saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GA, paracetamol, NSAID (GA)
Number of subjects: 60
Study: 9741867

Group type: EXPERIMENTAL
Intervention: Dietary intervention (60% of participants)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control (40% of participants)
Number of subjects: 750
Study: 7704350

Group type: EXPERIMENTAL
Intervention: Healthy volunteers in a clinical trial
Number of subjects: 300

Group type: COMPARATOR
Intervention: Breast cancer patients in a clinical trial
Number of subjects: 300
Study: 3138609

Group type: EXPERIMENTAL
Intervention: Low-dose animal antigen injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Indomethacin pretreatment
Number of subjects: 21
Study: 29868833

Group type: EXPERIMENTAL
Intervention: Continue ART (CTART)
Number of subjects: 1652

Group type: COMPARATOR
Intervention: Discontinue ART (DCART)
Number of subjects: 1652
Study: 28973650

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine with 150 μg clonidine (clonidine group, n = 116)
Number of subjects: 225

Group type: COMPARATOR
Intervention: 20 mL of 0.25% bupivacaine alone (control group, n = 109)
Number of subjects: 225
Study: 26519614

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction plus treatment as usual
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 55
Study: 24480956

Group type: EXPERIMENTAL
Intervention: 0.3 mg of ramosetron
Number of subjects: 196

Group type: COMPARATOR
Intervention: 0.075 mg of palonosetron
Number of subjects: 196
Study: 22051893

Group type: EXPERIMENTAL
Intervention: Full attention in the left visual field (LVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full attention in the right visual field (RVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor attention in the left visual field (LVF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor attention in the right visual field (RVF)
Number of subjects: 0
Study: 21149771

Group type: EXPERIMENTAL
Intervention: 2-hour daily patching of the sound eye
Number of subjects: 88

Group type: COMPARATOR
Intervention: 5 sessions of acupuncture weekly
Number of subjects: 88
Study: 17717119

Group type: EXPERIMENTAL
Intervention: Concentric resistance training (Con)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (Ecc)
Number of subjects: 21
Study: 16110015

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 449

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2
Number of subjects: 449
Study: 11931319

Group type: EXPERIMENTAL
Intervention: Sharply filtered bands of speech presented at various signal-to-noise ratios (SNRs) ranging from -25 to 41 dB.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paired bands of speech with one band held constant while varying the level and SNR of the other band.
Number of subjects: 100
Study: 10064757

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study: 8540115

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) + transrectal ultrasonography (TRUS)
Number of subjects: 2730

Group type: COMPARATOR
Intervention: Prostate-specific antigen (PSA)
Number of subjects: 2730
Study: 2399915

Group type: EXPERIMENTAL
Intervention: 100/serum creatinine
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Creatinine clearance estimated by the Cockcroft and Gault formula
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Simultaneously measured creatinine clearance
Number of subjects: 136
Study: 6902630

Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Wound irrigation and debridement
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Suturing wounds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cultures of wounds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus
Number of subjects: 57
Study: 30874295

Group type: EXPERIMENTAL
Intervention: Self-Reported Neglect Scale (SRNS)
Number of subjects: 2443
Study: 31840075

Group type: EXPERIMENTAL
Intervention: Winning Swiss citizenship in the referendum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losing Swiss citizenship in the referendum
Number of subjects: 0
Study: 27423977

Group type: EXPERIMENTAL
Intervention: Nurse Intervention (NI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 41
Study: 26035724

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) combined with Balance Coordination Exercises (BCEs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Home-based Balance Coordination Exercises (BCEs)
Number of subjects: 42
Study: 24695721

Group type: EXPERIMENTAL
Intervention: Baclofen (60 mg/d; 20 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22330092

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Reducing cigarette consumption
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 539

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 539

Group type: COMPARATOR
Intervention: Motivational interviewing
Number of subjects: 539
Study: 19737998

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC)
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC)
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC) in nonsquamous NSCLC subgroup
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC) in nonsquamous NSCLC subgroup
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (AC) in squamous cell histology subgroup
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GC) in squamous cell histology subgroup
Number of subjects: 1725
Study: 17992118

Group type: COMPARATOR
Intervention: Metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1+)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above plus rofecoxib 25 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metronomic chemotherapy (arm A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combined anti-inflammatory/angiostatic treatment (arm B)
Number of subjects: 76
Study: 15224207

Group type: EXPERIMENTAL
Intervention: Addition of rosiglitazone (4 mg b.i.d.) to gliclazide (160 mg/day)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Uptitration of gliclazide to a maximum of 320 mg/day
Number of subjects: 471
Study: 11786526

Group type: EXPERIMENTAL
Intervention: LY333531 (protein kinase Cbeta inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9849243

Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning based on assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine endotracheal suctioning every 2 hours
Number of subjects: 0
Study: 7926075

Group type: EXPERIMENTAL
Intervention: Laser laparoscopic surgery (laser ablation of endometriotic deposits and laparoscopic uterine nerve ablation)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 63
Study: 1522926

Group type: EXPERIMENTAL
Intervention: Indwelling catheter for 48 hours (group 1)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Catheterisation on indication only (group 2)
Number of subjects: 61